TW-37

For research use only.

Catalog No.S1121

38 publications

TW-37 Chemical Structure

CAS No. 877877-35-5

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 146 In stock
USD 160 In stock
USD 680 In stock
USD 1480 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's TW-37 has been cited by 38 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;IW5RSUW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYhdk1? NVTZdIJ2W0GQR1XS
human Ca9-22 cell NHLMeIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUPWNYxxUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh{IH7N MU\TRW5ITVJ?
human CHL-1 cell M{e5O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MofpTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlkhdk1? Mn23V2FPT0WU
human A549 cell M{HHVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoC0TY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUSuNFkhdk1? MX7TRW5ITVJ?
human RKO cell NHnVcYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF3LkG3JI5O NXv5UopLW0GQR1XS
human GCIY cell M33Cemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXu4Sm0yUW6qaXLpeIlwdiCxZjDoeY1idiCJQ1nZJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlAvQDNibl2= NF7a[pBUSU6JRWK=
human BHT-101 cell NXOyUGc5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXzPe2N[UW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwOEOgcm0> MlL4V2FPT0WU
human Hs-578-T cell MnzNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnnHTY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{NjV7IH7N MnXaV2FPT0WU
human SK-UT-1 cell MoTNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2H1bWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjZ6IH7N MlXRV2FPT0WU
human NB7 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWPucJBmUW6qaXLpeIlwdiCxZjDoeY1idiCQQkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU4zQCCwTR?= MVXTRW5ITVJ?
human YKG-1 cell MnmzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\XWW5DUW6qaXLpeIlwdiCxZjDoeY1idiC\S1etNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI6Njd4IH7N NYrnUo9LW0GQR1XS
human HuH-7 cell NYnyW3Q4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1:5[mlvcGmkaYTpc44hd2ZiaIXtZY4hUHWKLUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNk45OiCwTR?= NX\HTZRRW0GQR1XS
human SAS cell NIfQN3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFi1SGZKdmirYnn0bY9vKG:oIHj1cYFvKFODUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOzMlE5KG6P MUfTRW5ITVJ?
human UACC-62 cell MlnuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE4{PSCwTR?= NVy1[FFlW0GQR1XS
human AGS cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1rBPGlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{euOVMhdk1? NF7NO2ZUSU6JRWK=
human SK-MEL-30 cell NELndYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnnFTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Py57NzDuUS=> MYXTRW5ITVJ?
human A427 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12ND62PUBvVQ>? M4XKWHNCVkeHUh?=
human DU-145 cell NEDMNVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFjOO41KdmirYnn0bY9vKG:oIHj1cYFvKESXLUG0OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUzNjF|IH7N M2jifXNCVkeHUh?=
human HCT-116 cell M1zocmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Nk43PiCwTR?= NF3MNnRUSU6JRWK=
human A673 cell Mo\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGE3PzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Mz64OUBvVQ>? NITLOolUSU6JRWK=
human SF126 cell NGPVNJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIjqeHZKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVcvODdibl2= MlPUV2FPT0WU
human SW872 cell Mkf6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfLbJZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVgvQSCwTR?= NIPsOJRUSU6JRWK=
human NCI-H1581 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXqUYZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU5OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ5Lk[0JI5O MmLDV2FPT0WU
human SK-MEL-5 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmL1TY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVY6NjJ3IH7N NIPmTXlUSU6JRWK=
human CP50-MEL-B cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4DIb2lvcGmkaYTpc44hd2ZiaIXtZY4hS1B3MD3NSWwuSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ7LkW5JI5O MYnTRW5ITVJ?
human YH-13 cell NFftd|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;oXGlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23NE42QSCwTR?= MV7TRW5ITVJ?
human LXF-289 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV\6U29EUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PzJwOEWgcm0> M1vWSXNCVkeHUh?=
human MC-IXC cell M3zIW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXrCdldkUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04PS5|MzDuUS=> NFXWSIVUSU6JRWK=
human NB14 cell M3PsS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFi5NY9KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Ok41PSCwTR?= NEm2VmpUSU6JRWK=
human HEC-1 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn3zTY5pcWKrdHnvckBw\iCqdX3hckBJTUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUixMlM4KG6P NXzqbpU3W0GQR1XS
human U-87-MG cell NXvLSGlDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI\6UGtKdmirYnn0bY9vKG:oIHj1cYFvKFVvOEetUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Oi5{NDDuUS=> Mle5V2FPT0WU
human HOS cell NHLHWYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1XhOGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OESuO|Ehdk1? NYDPbIZKW0GQR1XS
human HUTU-80 cell Ml\lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DKOGlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg4NjBzIH7N M{HGb3NCVkeHUh?=
human A375 cell NVLMb41lT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXixbnlsUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFgvQDNibl2= MYDTRW5ITVJ?
human A204 cell NUfCbXR{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Nz64OEBvVQ>? Ml\XV2FPT0WU
human GB-1 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGfBV2RKdmirYnn0bY9vKG:oIHj1cYFvKEeELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25PE43QSCwTR?= MlXoV2FPT0WU
human MDA-MB-231 cell M{HYS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyOEC3JO69VQ>? MlnSV2FPT0WU
human SW982 cell NITjPIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEn4RYRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTB5IN88US=> Mn:3V2FPT0WU
human SW756 cell NXLiNplMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4r3cGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5NU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjN4IN88US=> M2nHWnNCVkeHUh?=
human MG-63 cell MmX5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrNZm5KdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTJ2ODFOwG0> NEft[lJUSU6JRWK=
human Daoy cell MkKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmXHTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOFA4OyEQvF2= NU\qc2lGW0GQR1XS
human MDA-MB-453 cell NXn2OpA6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{PxWWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ2OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUWxPFgh|ryP MmDPV2FPT0WU
human HT-144 cell M3HLeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVUzODFizszN MoXLV2FPT0WU
human LoVo cell NVLSZZJqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWn4NWlUUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjB7MzFOwG0> NUTMXXRqW0GQR1XS
human NY cell Mn;US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{TDNGlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG3O|YzKM7:TR?= NX2yPZFFW0GQR1XS
human SW1783 cell M1jkemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE{ODFizszN NGDld45USU6JRWK=
human A2780 cell NUPk[JNqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mk\RTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE5PDZizszN MUPTRW5ITVJ?
human MDA-MB-361 cell NXPFOYxOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnvLTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN|YyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Mk[0JO69VQ>? M4rNO3NCVkeHUh?=
human RPMI-2650 cell M1vUSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NE\zcWpKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtNlY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkO4N|Eh|ryP NUHWc4VOW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol

Kinase Assay:[1]
- Collapse

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
Cell Research:[2]
- Collapse
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID